←
Roth_Lab47 posts
Roth_Lab avatar

Roth_Lab

@Roth_Lab

Genetic Technologies and New Gene Design for Curative Therapies @Stanford - @parkerici - @arcinstitute

◷ Joined November 2025▧ 29 Photos and videos
Cell avatar
⟳ Roth_Lab retweeted
Cell@CellCellPress·Sep 24

In the latest issue! Synthetic transcription factors designed by domain recombination enhance CAR T cell antitumor function dlvr.it/TVdDXq

Roth_Lab avatar
Roth_Lab@Roth_Lab·Aug 19

This has been a huge effort from Oliver, everyone in the Roth Lab and the Satpathy Lab, and an amazing group of collaborators. None of this type of work is possible without high risk-high reward funding, especially from the @arcinstitute, the @NIH Director ‘s New Innovator Award, and @PICI, @Burroughs Wellcome, and the @Weill Foundation

Roth_Lab avatar
Roth_Lab@Roth_Lab·Aug 19

Much more functional and mechanistic details about individual top DESynR AP-1 TFs in the full manuscript! But it is exciting to propose that the human genomes natural set of 20,000 genes may not be the only “human” genes that can be productively manipulated when studying human biology, building cellular therapies, or predictively designing optimal genetic perturbations for desired tasks. (9/10) x.com/Satpathology/status/20…

Human protein-coding genes evolved from old parts - reconfigured domains from ancestral genes. We can screen short-sequence evolution at scale using mutagenesis, CRISPR, etc, but we had no way to do the same for domain-level evolution. Happy to share our work developing DESynR genes today in @CellCellPress: scalable synthesis and functional screening of thousands of new human genes, built from old parts. DESynR transcription factors outperform native factors and dramatically improve CAR T cell function. A team effort led by the incredible Oliver Takacsi-Nagy! @parkerici @CancerResearch @TheMarkFdn cell.com/cell/fulltext/S0092…

Roth_Lab avatar
Roth_Lab@Roth_Lab·Aug 19

Importantly, it was the unique combination of existing natural domains into a new combined DESynR human AP-1 TF, rather than overexpression of each domain individually or each contributing natural AP-1 TF individually, that programmed the full extent of improved functional behavior. (8/10)

Post attachment
Roth_Lab avatar
Roth_Lab@Roth_Lab·Aug 19

Excitingly, to some extent top DESynR AP-1 TFs appeared to access these unique functional patterns by programming new transcriptional states not seen in base CAR T cells or with natural TF overexpression. (7/10)

Post attachment
Roth_Lab avatar
Roth_Lab@Roth_Lab·Aug 19

Across a much wider array of functional assays in primary human T cells, DESynR AP-1 TFs showed unique and potentially improved patterns of functional behavior compared to natural AP-1 TFs or otherwise unmodified CAR T cells. (6/10)

Post attachment
Roth_Lab avatar
Roth_Lab@Roth_Lab·Aug 19

For instance, a synthetic combination of BATF3’s N terminal effector domain, ATF3’s b-zip DNA binding domain, and BATF2’s C terminal effector domain, drove much greater proliferation in a long term repetitive stimulation assay than any natural AP-1 TF. (5/10)

Post attachment
Roth_Lab avatar
Roth_Lab@Roth_Lab·Aug 19

Functional screening of these DESynR AP-1 TFs revealed numerous new human AP-1 TFs that outperformed overexpression of any natural AP-1 TF. (4/10)

Post attachment
Roth_Lab avatar
Roth_Lab@Roth_Lab·Aug 19

We focused on the AP-1 family of basic lucine zipper TFs - they are both some of the most highly expressed in the genome (think Jun, Fos), as well as enriched in previous knockout and overexpression hits from prior natural gene screening in human T cell models. There are 24 natural human AP-1 TFs. We built over 13,000 new “DESynR” AP-1 TFs that the human genome could have constructed from existing AP1 TF domains. (3/10)

Post attachment
Roth_Lab avatar
Roth_Lab@Roth_Lab·Aug 19

Eukaryotic genomes most commonly acquire new genes through duplication of existing genes followed by recombination. We set out to experimentally mimic and accelerate this process, building, integrating into a primary human T cell’s genome, and functionally testing over 10,000 new human transcription factors in a single experiment. (2/10)

Post attachment
Roth_Lab avatar
Roth_Lab@Roth_Lab·Aug 19

Transcription Factors are central to cellular identity and function. The human genome currently contains ~1600 of them. But could there be productive human transcription factors that have not evolved? Out today in Cell, a tremendously talented graduate student Oliver Takacsi-Nagy @Oli_TN, together with the @Satpathology Lab, determined to find out. (1/10) authors.elsevier.com/sd/arti…

Post attachment
AACR avatar
⟳ Roth_Lab retweeted
AACR@AACR·Apr 19

Congratulations to the AACR Trailblazer Cancer Research Grants recipients, supported by @pfizer. AACR’s largest-ever grant program has awarded 15 early-stage and mid-career investigators $1million each to establish novel, highly creative research projects. brnw.ch/21x1JQA

Post attachment
Roth_Lab avatar
Roth_Lab@Roth_Lab·Apr 10

We hope GLIDE-editing may be of use for research and clinical applications requiring integration of ever larger, more powerful DNA sequences into the human genome. None of this is possible without the support of our funders, @theNCI, @NIH New Innovator Award, @arcinstitute, @parkerici, @BWFUND, the Weill Foundation, and the Cancer League (11/11)

Roth_Lab avatar
Roth_Lab@Roth_Lab·Apr 10

This has been a long running collaborative effort, run by exceptional future PhD students Courtney Kernick and Lauren Chow, and an entire team between Brian Shy’s and Greg Allen’s Labs at @UCSF and @GladstoneInst and our group @Stanford and @arcinstitute (10/11)

Roth_Lab avatar
Roth_Lab@Roth_Lab·Apr 10

More broadly beyond ex vivo electroporation based T cell and iPSC editing, we characterized head-to-head toxicity, delivery, editing efficiency, and manufacturability properties for a comprehensive series of linear and circular, single stranded and double stranded DNA templates, hopefully of use as a reference across applications requiring intracellular DNA delivery. (9/11)

Post attachment
Roth_Lab avatar
Roth_Lab@Roth_Lab·Apr 10

Ultra-large DNA integrations were compatible with clinical T cell manufacturing, and these cells were functional in vitro and in vivo, which will allow for clinical translation of more powerful genetically engineered cellular therapies. (8/11)

Post attachment